Stock Yards Bank & Trust Co. Has $709,000 Stock Holdings in Astrazeneca Plc $AZN

Stock Yards Bank & Trust Co. lessened its stake in shares of Astrazeneca Plc (NYSE:AZN) by 49.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,594 shares of the company’s stock after selling 3,520 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Astrazeneca were worth $709,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in AZN. Triumph Capital Management bought a new position in Astrazeneca during the third quarter worth about $25,000. MV Capital Management Inc. bought a new stake in shares of Astrazeneca in the 4th quarter valued at about $26,000. Bangor Savings Bank increased its stake in shares of Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca in the 4th quarter valued at approximately $30,000. Finally, YANKCOM Partnership bought a new position in Astrazeneca during the 4th quarter worth approximately $31,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $194.96 on Friday. The company has a fifty day moving average price of $183.91 and a 200 day moving average price of $187.76. The firm has a market cap of $302.36 billion, a PE ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Research analysts predict that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday. Weiss Ratings cut shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research note on Tuesday. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Finally, Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca News Summary

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.